{"schema_version":"secwatch.filing_event.v1","accession":"0001559053-23-000002","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.565789+00:00","generated_at":"2026-06-19T02:36:00.227187+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Prothena reports Q4 net income $6.3M, full year net loss $116.9M; provides 2023 guidance","bullets":["Q4 2022 revenue $49.9M (incl. $40M Novo Nordisk milestone); full year revenue $53.9M vs $200.6M in 2021.","Cash, cash equivalents and restricted cash $712.6M at Dec 31, 2022; no debt.","2023 guidance: net cash used in operating/investing $213-229M; year-end cash ~$512M.","PRX012 Phase 1 topline data expected year-end 2023; PRX005 Phase 1 MAD topline also year-end 2023.","Birtamimab Phase 3 AFFIRM-AL topline data expected 2024; prasinezumab Phase 2b topline 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001559053-23-000002","json":"https://secwatch.observer/filing/0001559053-23-000002.json","markdown":"https://secwatch.observer/filing/0001559053-23-000002.md","text":"https://secwatch.observer/filing/0001559053-23-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000155905323000002/0001559053-23-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000155905323000002/prta-20230223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T02:36:00.227187+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}